Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve.

ABSTRACT: The phosphoinositide kinase PIKfyve has emerged as a new potential therapeutic target in various cancers. However, limited clinical progress has been achieved with PIKfyve inhibitors. Here, we report the discovery of a first-in-class PIKfyve degrader 12d (PIK5-12d) by employing the proteolysis-targeting chimera approach. PIK5-12d potently degraded PIKfyve protein with a DC₅₀ value of 1.48 nM and a D_max value of 97.7% in prostate cancer VCaP cells. Mechanistic studies revealed that it selectively induced PIKfyve degradation in a VHL- and proteasome-dependent manner. PIKfyve degradation by PIK5-12d caused massive cytoplasmic vacuolization and blocked autophagic flux in multiple prostate cancer cell lines. Importantly, PIK5-12d was more

SUBMITTER: Li C 

PROVIDER: S-EPMC10510382 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature